Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

1.

Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.

Heller G, Kattan MW, Scher HI.

Med Decis Making. 2007 Jul-Aug;27(4):380-6.

PMID:
17761958
[PubMed - indexed for MEDLINE]
2.

Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.

Verbel DA, Kelly WK, Smaletz O, Regan K, Curley T, Heller G, Scher HI.

Urology. 2003 Jan;61(1):142-4.

PMID:
12559285
[PubMed - indexed for MEDLINE]
3.

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.

Fazzari M, Heller G, Scher HI.

Control Clin Trials. 2000 Aug;21(4):360-8.

PMID:
10913810
[PubMed - indexed for MEDLINE]
4.

A standardization method to adjust for the effect of patient selection in phase II clinical trials.

Mazumdar M, Fazzari M, Panageas KS.

Stat Med. 2001 Mar 30;20(6):883-92.

PMID:
11252010
[PubMed - indexed for MEDLINE]
5.

The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.

Nixon RM, O'Hagan A, Oakley J, Madan J, Stevens JW, Bansback N, Brennan A.

Pharm Stat. 2009 Oct-Dec;8(4):371-89. doi: 10.1002/pst.368.

PMID:
19340851
[PubMed - indexed for MEDLINE]
6.

Design of Phase II cancer trials evaluating survival probabilities.

Case LD, Morgan TM.

BMC Med Res Methodol. 2003 Apr 3;3:6. Epub 2003 Apr 3.

PMID:
12697051
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Picking the winners in a sea of plenty.

Scher HI, Heller G.

Clin Cancer Res. 2002 Feb;8(2):400-4.

PMID:
11839655
[PubMed - indexed for MEDLINE]
Free Article
8.

Use of predictive probabilities in phase II and phase III clinical trials.

Johns D, Andersen JS.

J Biopharm Stat. 1999 Mar;9(1):67-79.

PMID:
10091910
[PubMed - indexed for MEDLINE]
9.

The group sequential triangular test for phase II cancer clinical trials.

Bellissant E, BĂ©nichou J, Chastang C.

Am J Clin Oncol. 1996 Aug;19(4):422-30.

PMID:
8677918
[PubMed - indexed for MEDLINE]
10.

Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.

Taylor JM, Braun TM, Li Z.

Clin Trials. 2006;3(4):335-48.

PMID:
17060208
[PubMed - indexed for MEDLINE]
11.

Adapting the sample size planning of a phase III trial based on phase II data.

Wang SJ, Hung HM, O'Neill RT.

Pharm Stat. 2006 Apr-Jun;5(2):85-97.

PMID:
17080765
[PubMed - indexed for MEDLINE]
12.

Play the winner for phase II/III clinical trials.

Yao Q, Wei LJ.

Stat Med. 1996 Nov 15-30;15(21-22):2413-23; discussion 2455-8.

PMID:
8931210
[PubMed - indexed for MEDLINE]
13.

Optimal two-stage designs for clinical trials based on safety and efficacy.

Thall PF, Cheng SC.

Stat Med. 2001 Apr 15;20(7):1023-32.

PMID:
11276033
[PubMed - indexed for MEDLINE]
14.

Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.

[No authors listed]

Drugs R D. 2007;8(5):321-34. Review.

PMID:
17767397
[PubMed - indexed for MEDLINE]
15.

Interim futility analysis with intermediate endpoints.

Goldman B, LeBlanc M, Crowley J.

Clin Trials. 2008;5(1):14-22. doi: 10.1177/1740774507086648.

PMID:
18283075
[PubMed - indexed for MEDLINE]
16.

Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.

Choi L, Dominici F, Zeger SL, Ouyang P.

Stat Med. 2005 Sep 30;24(18):2789-805.

PMID:
16134133
[PubMed - indexed for MEDLINE]
17.

Clinical experience with epothilones in patients with breast cancer.

Buzdar AU.

Clin Breast Cancer. 2008 Mar;8 Suppl 2:S71-8. Review.

PMID:
18637402
[PubMed - indexed for MEDLINE]
18.

A comparison of methods for phase II cancer clinical trials: advantages of the triangular test, a group sequential method.

Bellissant E, Benichou J, Chastang C.

Lung Cancer. 1994 Mar;10 Suppl 1:S105-15. Review.

PMID:
8087499
[PubMed - indexed for MEDLINE]
19.

A flexible design for multiple armed screening trials.

Sargent DJ, Goldberg RM.

Stat Med. 2001 Apr 15;20(7):1051-60.

PMID:
11276035
[PubMed - indexed for MEDLINE]
20.

Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.

Schmidli H, Bretz F, Racine-Poon A.

Stat Med. 2007 Nov 30;26(27):4925-38.

PMID:
17590875
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk